Longwood Fund is a venture capital firm that focuses on creating and investing in early-stage, science-based companies within the healthcare, pharmaceutical, and biotechnology sectors. Their strategy involves actively co-founding companies, often taking operational leadership roles, and providing hands-on support to accelerate the development of novel therapies for unmet medical needs.
Portfolio
6
Fund Size
$650M
Top Stage
Series A
Last 12 Mo
2
Stage Distribution
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Mediar Therapeutics, Inc. | Series B | $76M | Jan 2026 |
| Solu Therapeutics | Series A | $41M | Apr 2025 |
| Interius BioTherapeutics | Series A | $76M | May 2021 |
| Werewolf Therapeutics | Series A | $56M | Nov 2019 |
| Pyxis Oncology | Series A | $22M | Jul 2019 |
| Sitryx Therapeutics | Series A | $30M | Oct 2018 |
Top Co-Investors
Agent Capital2 shared
Bain Capital Life Sciences1 shared
Cormorant Asset Management1 shared
Pfizer Ventures1 shared
RA Capital Management1 shared
Logos Capital1 shared
Osage University Partners1 shared
Knollwood1 shared
BrightEdge1 shared
Amplitude Ventures1 shared
MPM Capital1 shared
UPMC Enterprises1 shared
Eli Lilly and Company1 shared
Pappas Capital1 shared
DCVC Bio1 shared
Astellas Venture Management1 shared
Alexandria Venture Investments1 shared
Leaps by Bayer1 shared
SV Health Investors1 shared
Sofinnova Partners1 shared
Last updated: 3 March 2026